Addex Therapeutics shares are trading higher after the company and Indivior selected clinical candidates from their GABAB positive allosteric modulator research collaboration. The company is eligible for up to $330 million on achievement of milestones and royalties.
Portfolio Pulse from Benzinga Newsdesk
Addex Therapeutics shares rose as the company, in collaboration with Indivior, selected clinical candidates from their GABAB positive allosteric modulator research. Addex is eligible for up to $330 million in milestone payments and royalties.
August 27, 2024 | 11:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Addex Therapeutics' stock is trading higher following the selection of clinical candidates in collaboration with Indivior. The potential for up to $330 million in milestone payments and royalties is a significant financial opportunity.
The selection of clinical candidates in collaboration with Indivior is a positive development for Addex Therapeutics, indicating progress in their research. The potential for substantial milestone payments and royalties provides a strong financial incentive, likely boosting investor confidence and driving the stock price up.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90